The CD20 inhibitor Briumvi (ublituximab) significantly outperformed Aubagio (teriflunomide) at lowering relapse rates and reducing disease activity on brain MRI scans in people with highly active relapsing forms of multiple sclerosis (MS). That’s according to a new analysis of pooled data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical studies, which […]
The post Briumvi outperforms Aubagio in highly active relapsing MS: Study appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com